Cargando…

Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH

BACKGROUND: Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells. Immunotoxins exhibit effective cytotoxicity and have been approved by the FDA to treat multiple hematological malignancies, such as hair...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyu, Tan, Qingqing, Wen, Jiaqi, Wang, Xufei, Yang, Gang, Li, Yuxiao, Lu, Ming, Ye, Wei, Si, Anfeng, Ma, Sujuan, Ding, Tong, Sun, Luan, Liu, Fang, Zhang, Mei, Jiang, Tao, Gao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463491/
https://www.ncbi.nlm.nih.gov/pubmed/37626430
http://dx.doi.org/10.1186/s12967-023-04210-7
_version_ 1785098244816109568
author Liu, Xiaoyu
Tan, Qingqing
Wen, Jiaqi
Wang, Xufei
Yang, Gang
Li, Yuxiao
Lu, Ming
Ye, Wei
Si, Anfeng
Ma, Sujuan
Ding, Tong
Sun, Luan
Liu, Fang
Zhang, Mei
Jiang, Tao
Gao, Wei
author_facet Liu, Xiaoyu
Tan, Qingqing
Wen, Jiaqi
Wang, Xufei
Yang, Gang
Li, Yuxiao
Lu, Ming
Ye, Wei
Si, Anfeng
Ma, Sujuan
Ding, Tong
Sun, Luan
Liu, Fang
Zhang, Mei
Jiang, Tao
Gao, Wei
author_sort Liu, Xiaoyu
collection PubMed
description BACKGROUND: Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells. Immunotoxins exhibit effective cytotoxicity and have been approved by the FDA to treat multiple hematological malignancies, such as hairy cell leukemia and cutaneous T-cell lymphoma. However, most of the internalized immunotoxin is degraded in lysosomes, and only approximately 5% of free toxin escapes into the cytosol to exert cytotoxicity. Many studies have improved immunotoxins by engineering the toxin fragment to reduce immunogenicity or increase stability, but how the antibody fragment contributes to the activity of immunotoxins has not been well demonstrated. METHODS: In the current study, we used 32A9 and 42A1, two anti-GPC3 antibodies with similar antigen-binding capabilities and internalization rates, to construct scFv-mPE24 immunotoxins and evaluated their in vitro and in vivo antitumor activities. Next, the antigen-binding capacity, trafficking, intracellular protein stability and release of free toxin of 32A9 scFv-mPE24 and 42A1 scFv-mPE24 were compared to elucidate their different antitumor activities. Furthermore, we used a lysosome inhibitor to evaluate the degradation behavior of 32A9 scFv-mPE24 and 42A1 scFv-mPE24. Finally, the antigen-binding patterns of 32A9 and 42A1 were compared under neutral and acidic pH conditions. RESULTS: Although 32A9 and 42A1 had similar antigen binding capacities and internalization rates, 32A9 scFv-mPE24 had superior antitumor activity compared to 42A1 scFv-mPE24. We found that 32A9 scFv-mPE24 exhibited faster degradation and drove efficient free toxin release compared to 42A1 scFv-mPE24. These phenomena were determined by the different degradation behaviors of 32A9 scFv-mPE24 and 42A1 scFv-mPE24 in lysosomes. Moreover, 32A9 was sensitive to the low-pH environment, which made the 32A9 conjugate easily lose antigen binding and undergo degradation in lysosomes, and the free toxin was then efficiently produced to exert cytotoxicity, whereas 42A1 was resistant to the acidic environment, which kept the 42A1 conjugate relatively stable in lysosomes and delayed the release of free toxin. CONCLUSIONS: These results showed that a low pH-sensitive antibody-based immunotoxin degraded faster in lysosomes, caused effective free toxin release, and led to improved cytotoxicity compared to an immunotoxin based on a normal antibody. Our findings suggested that a low pH-sensitive antibody might have an advantage in the design of immunotoxins and other lysosomal degradation-dependent antibody conjugate drugs.
format Online
Article
Text
id pubmed-10463491
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104634912023-08-30 Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH Liu, Xiaoyu Tan, Qingqing Wen, Jiaqi Wang, Xufei Yang, Gang Li, Yuxiao Lu, Ming Ye, Wei Si, Anfeng Ma, Sujuan Ding, Tong Sun, Luan Liu, Fang Zhang, Mei Jiang, Tao Gao, Wei J Transl Med Research BACKGROUND: Immunotoxins are antibody-toxin conjugates that bind to surface antigens and exert effective cytotoxic activity after internalization into tumor cells. Immunotoxins exhibit effective cytotoxicity and have been approved by the FDA to treat multiple hematological malignancies, such as hairy cell leukemia and cutaneous T-cell lymphoma. However, most of the internalized immunotoxin is degraded in lysosomes, and only approximately 5% of free toxin escapes into the cytosol to exert cytotoxicity. Many studies have improved immunotoxins by engineering the toxin fragment to reduce immunogenicity or increase stability, but how the antibody fragment contributes to the activity of immunotoxins has not been well demonstrated. METHODS: In the current study, we used 32A9 and 42A1, two anti-GPC3 antibodies with similar antigen-binding capabilities and internalization rates, to construct scFv-mPE24 immunotoxins and evaluated their in vitro and in vivo antitumor activities. Next, the antigen-binding capacity, trafficking, intracellular protein stability and release of free toxin of 32A9 scFv-mPE24 and 42A1 scFv-mPE24 were compared to elucidate their different antitumor activities. Furthermore, we used a lysosome inhibitor to evaluate the degradation behavior of 32A9 scFv-mPE24 and 42A1 scFv-mPE24. Finally, the antigen-binding patterns of 32A9 and 42A1 were compared under neutral and acidic pH conditions. RESULTS: Although 32A9 and 42A1 had similar antigen binding capacities and internalization rates, 32A9 scFv-mPE24 had superior antitumor activity compared to 42A1 scFv-mPE24. We found that 32A9 scFv-mPE24 exhibited faster degradation and drove efficient free toxin release compared to 42A1 scFv-mPE24. These phenomena were determined by the different degradation behaviors of 32A9 scFv-mPE24 and 42A1 scFv-mPE24 in lysosomes. Moreover, 32A9 was sensitive to the low-pH environment, which made the 32A9 conjugate easily lose antigen binding and undergo degradation in lysosomes, and the free toxin was then efficiently produced to exert cytotoxicity, whereas 42A1 was resistant to the acidic environment, which kept the 42A1 conjugate relatively stable in lysosomes and delayed the release of free toxin. CONCLUSIONS: These results showed that a low pH-sensitive antibody-based immunotoxin degraded faster in lysosomes, caused effective free toxin release, and led to improved cytotoxicity compared to an immunotoxin based on a normal antibody. Our findings suggested that a low pH-sensitive antibody might have an advantage in the design of immunotoxins and other lysosomal degradation-dependent antibody conjugate drugs. BioMed Central 2023-08-25 /pmc/articles/PMC10463491/ /pubmed/37626430 http://dx.doi.org/10.1186/s12967-023-04210-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Xiaoyu
Tan, Qingqing
Wen, Jiaqi
Wang, Xufei
Yang, Gang
Li, Yuxiao
Lu, Ming
Ye, Wei
Si, Anfeng
Ma, Sujuan
Ding, Tong
Sun, Luan
Liu, Fang
Zhang, Mei
Jiang, Tao
Gao, Wei
Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title_full Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title_fullStr Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title_full_unstemmed Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title_short Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH
title_sort improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic ph
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463491/
https://www.ncbi.nlm.nih.gov/pubmed/37626430
http://dx.doi.org/10.1186/s12967-023-04210-7
work_keys_str_mv AT liuxiaoyu improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT tanqingqing improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT wenjiaqi improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT wangxufei improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT yanggang improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT liyuxiao improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT luming improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT yewei improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT sianfeng improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT masujuan improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT dingtong improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT sunluan improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT liufang improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT zhangmei improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT jiangtao improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph
AT gaowei improvingthecytotoxicityofimmunotoxinsbyreducingtheaffinityoftheantibodyinacidicph